Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.32 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16329608 | 0.94 | SLC6A1 (0.34) | KIF11SLC6A1SLC6A11KCNH2 | |
| SCHEMBL27050962 | 0.94 | SLC6A1 (0.34) | KIF11SLC6A1SLC6A11KCNH2 | |
| SCHEMBL2820572 | 0.94 | SLC6A1 (0.34) | KIF11SLC6A1SLC6A11KCNH2 | |
| SCHEMBL25764740 | 0.94 | SLC6A1 (0.34) | KIF11SLC6A1SLC6A11KCNH2 | |
| SCHEMBL31636266 | 0.93 | SLC6A1 (0.31) | SLC6A1SLC6A11 | |
| SCHEMBL2472575 | 0.92 | SLC6A11 (0.35) | KIF11SLC6A1SLC6A11KCNH2 | |
| SCHEMBL30116036 | 0.91 | KIF11 (0.34) | KIF11SLC6A1SLC6A11KCNH2 | |
| SCHEMBL30116106 | 0.91 | KIF11 (0.34) | KIF11SLC6A1SLC6A11KCNH2 | |
| SCHEMBL17166451 | 0.91 | ALDH1A1 (0.33) | SLC6A11 | |
| SCHEMBL8332233 | 0.88 | ALDH1A1 (0.33) | SLC6A1SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729617-A1 | APTAMER TARGETING CD25, DRUG CONJUGATE COMPRISING SAME, AND USE THEREOF | Aptamer Sciences Inc. (KR) | 2026-04-22 | — | — | EP | claimed |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | LONZA SALES AG (CH) | 2026-01-29 | — | — | US | claimed |
| US-20250382613-A1 | METHODS OF USING EXTRACELLULAR VESICLE-ASO TARGETING STAT6 | LONZA SALES AG (CH) | 2025-12-18 | — | — | US | claimed |
| EP-4562156-A2 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | Lonza Sales AG (CH) | 2025-06-04 | — | — | EP | claimed |
| EP-4547259-A2 | METHODS OF USING EXTRACELLULAR VESICLE-ASO TARGETING STAT6 | Lonza Sales AG (CH) | 2025-05-07 | — | — | EP | claimed |
| CN-119948163-A | CEBP/beta targeted extracellular vesicle-ASO constructs | 隆萨销售股份有限公司 | 2025-05-06 | — | — | CN | claimed |
| US-20250101415-A1 | DNA ORIGAMI STRUCTURE AND PROTEIN NANOPORE CONSTRUCT | ILLUMINA, INC. | 2025-03-27 | — | — | US | claimed |
| EP-4514997-A1 | DNA ORIGAMI STRUCTURE AND PROTEIN NANOPORE CONSTRUCT | ILLUMINA, INC. (US) | 2025-03-05 | — | — | EP | claimed |
| US-20250049927-A1 | MODIFIED OLIGONUCLEOTIDE-DRUG CONJUGATE AND USE THEREOF | INTEROLIGO CORPORATION. (KR) | 2025-02-13 | — | — | US | claimed |
| WO-2024257962-A1 | APTAMER TARGETING CD25, DRUG CONJUGATE COMPRISING SAME, AND USE THEREOF | 주식회사 압타머사이언스 | 2024-12-19 | — | — | WO | claimed |
| CN-114729327-A | Extracellular vesicles with STAT3 antisense oligonucleotides | 科迪亚克生物科学公司 | 2022-07-08 | — | — | CN | claimed |
| EP-4013876-A1 | EXTRACELLULAR VESICLE-NLRP3 ANTAGONIST | Codiak BioSciences, Inc. (US) | 2022-06-22 | — | — | EP | claimed |
| EP-4013877-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | Codiak BioSciences, Inc. (US) | 2022-06-22 | — | — | EP | claimed |
| EP-4013875-A1 | EXTRACELLULAR VESICLES WITH STAT3-ANTISENSE OLIGONUCLEOTIDES | Codiak BioSciences, Inc. (US) | 2022-06-22 | — | — | EP | claimed |
| EP-4013872-A1 | EXTRACELLULAR VESICLES WITH ANTISENSE OLIGONUCLEOTIDES TARGETING KRAS | Codiak BioSciences, Inc. (US) | 2022-06-22 | — | — | EP | claimed |
| EP-4013878-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | Codiak BioSciences, Inc. (US) | 2022-06-22 | — | — | EP | claimed |
| CN-114641570-A | Extracellular vesicles with KRAS-targeted antisense oligonucleotides | 科迪亚克生物科学公司 | 2022-06-17 | — | — | CN | claimed |
| CN-109863161-B | Labeled polynucleotides useful for nucleic acid sequencing | 豪夫迈·罗氏有限公司 | 2022-06-03 | — | — | CN | claimed |
| WO-2022076596-A9 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | CODIAK BIOSCIENCES, INC. (US) | 2022-05-12 | — | — | WO | claimed |
| WO-2022076596-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | CODIAK BIOSCIENCES, INC. (US) | 2022-04-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382613-A1 | METHODS OF USING EXTRACELLULAR VESICLE-ASO TARGETING STAT6 | STAT6, EXOSC5, STAT5B | KIF11 1834/4885SLC6A1 3858/4885SLC6A11 3377/4885 |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | CEBPZ, OSBP, DIS3 | KIF11 2898/4885SLC6A1 2858/4885SLC6A11 2326/4885 |
| US-20250049927-A1 | MODIFIED OLIGONUCLEOTIDE-DRUG CONJUGATE AND USE THEREOF | DCLRE1B, DUT, DCTD | KIF11 674/4885SLC6A1 3770/4885SLC6A11 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.